Rescue of exhausted CD8 T cells by PD-1–targeted therapies is CD28-dependent
Alice O. Kamphorst(Icahn School of Medicine at Mount Sinai), Rafi Ahmed(Emory University), Bogumila T. Konieczny(Emory University), Gabriel Sica(Emory University), Koichi Araki(Emory University), Lydia Koenig(Emory University), Ruan Zhang(Massachusetts General Hospital), Arlene H. Sharpe(Brigham and Women's Hospital), Laurence A. Turka(Harvard University), Daniel L. Barber(National Institute of Allergy and Infectious Diseases), Bruce R. Blazar(University of Minnesota Medical Center), Andreas Wieland(Emory University), Gordon J. Freeman(Dana-Farber Cancer Institute), Tahseen H. Nasti(Emory University), Suresh S. Ramalingam(Emory University), Yu Ke(Ministry of Education), Shu Yang(Central South University), Candace Daugherty(Emory University), Rathi N. Pillai(Emory University), Taofeek K. Owonikoko(UPMC Hillman Cancer Center)
Cited by 1,025
Related Papers
PD-1 and Its Ligands in Tolerance and Immunity
|Annual Review of Immunology|2008|5.3k
Osimertinib or Platinum–Pemetrexed in <i>EGFR</i> T790M–Positive Lung Cancer
|New England Journal of Medicine|2016|3.3k
PD-L2 is a second ligand for PD-1 and inhibits T cell activation
|Nature Immunology|2001|3k
PD-L1 regulates the development, maintenance, and function of induced regulatory T cells
|The Journal of Experimental Medicine|2009|2k
Immunology of COVID-19: Current State of the Science
|Immunity|2020|1.8k